Reidy-Lagunes DL, et al. - This retrospective series aspired to illustrate complete responses to mitotane in metastatic adrenocortical carcinoma. A low response rate and low tumor control rate of mitotane were highlighted in this study. However, a disproportionately high complete response rate suggested it should be used in selected individuals. With mitotane use, adrenal insufficiency was common.